Emergence of the concept of platelet reactivity monitoring of response to thienopyridines.
Heart
; 95(15): 1214-9, 2009 Aug.
Article
en En
| MEDLINE
| ID: mdl-19196732
ABSTRACT
Clinical trials have demonstrated the beneficial impact of clopidogrel in preventing major adverse cardiovascular events (MACE), particularly in patients undergoing percutaneous coronary intervention (PCI). The concept of biological clopidogrel resistance emerged with the finding of persistent platelet activation despite clopidogrel therapy in some patients. Further, a link between biological clopidogrel resistance and thrombotic recurrence after PCI was observed and a threshold of platelet reactivity (PR) for thrombotic events was suggested. Consistently, in recent trials, enhanced PR inhibition translated into a reduction in the rate of MACE after PCI. This review aims to present the emergence of the concept of PR monitoring in patients undergoing PCI following recent advances in this field.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Piridinas
/
Trombosis Coronaria
/
Ticlopidina
/
Inhibidores de Agregación Plaquetaria
/
Agregación Plaquetaria
Límite:
Humans
Idioma:
En
Revista:
Heart
Asunto de la revista:
CARDIOLOGIA
Año:
2009
Tipo del documento:
Article
País de afiliación:
Estados Unidos